- Coordinator
- Rise Research Institutes of Sweden AB, Sweden
- Runs
- 1 May 2025 to 30 April 2030
- Status
- Running
- EU funding
- €11.3m
- Total cost
- €19.8m
- Partners
- 46 organisations in 14 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101192133
What the project is doing
In the project's own words, from its summary on CORDIS.
CAREPATH aims to improve chronic disease management and medication persistence by transforming the care ecosystem, ensuring personalised support for better health outcomes, and reducing healthcare costs. We focus on improving medication adherence and persistence for three prevalent chronic conditions: Obesity (BMI ≥ 30 kg/m2), Type 2 Diabetes Mellitus (T2DM), and cardiovascular diseases (CVD), including chronic heart failure (CHF), across six diverse European countries: Germany, Israel, the Netherlands, Poland, Spain, and Sweden.
These countries represent various EU healthcare environments and economic statuses, emphasising the need for tailored approaches to patient care. Our strategy involves integrating localised non-digital and digital health solutions to address the unique healthcare delivery challenges in each region. The CAREPATH toolbox collects, combines, and customises existing solutions into adaptable modules for broad application in both primary and secondary care settings.
This toolbox will be tested in four studies across two settings in all six countries in both primary and secondary care. Three pilot studies in different regions as well as a proof-of-concept study in Germany will be conducted. This comprehensive evaluation, including HTA, aims to assess the toolbox's implementation and effectiveness, with a strong focus on learning what works for what groups of patients in which setting.
Recognizing the significant impact of obesity, particular emphasis is placed on treatment adherence and persistence of medications that facilitate weight loss, such as dual GIP/GLP-1 receptor agonists, but CAREPATH studies also include patients using lipid-lowering drugs, insulin, and SGLT2 inhibitors. Our goal is to empower patients by improving communication and data sharing among patients, healthcare providers, and other stakeholders, thereby supporting the entire ecosystem and alleviating the burden on healthcare systems.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Rise Research Institutes of Sweden AB | Boras | Sweden | Coordinator |
| Hl7 Europe | Bruxelles / Brussel | Belgium | Participant |
| Menarini Benelux | Machelen | Belgium | Associatedpartner |
| Iqvia AG | Rotkreuz | Switzerland | Participant |
| Abbott GmbH | Wiesbaden | Germany | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH | Neuherberg | Germany | Participant |
| Landschaftsverband Rheinland | Koln | Germany | Participant |
| Lilly Deutschland GmbH | Bad Homburg | Germany | Associatedpartner |
| Technische Universitaet Dresden | Dresden | Germany | Participant |
| Universitaet Leipzig | Leipzig | Germany | Participant |
| Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat | Wurzburg | Germany | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Asociación Bariátrica Híspalis Nacional | Santander | Spain | Participant |
| Fundacio Institut D'investigacio Sanitaria Illes Balears | Palma | Spain | Participant |
| Fundacio Institut Universitari Pera La Recerca a L'atencio Primaria De Salut Jordi Gol I Gurina | Barcelona | Spain | Third party |
| Institut Catala De La Salut | Barcelona | Spain | Participant |
| Institut De Investigacio En Ciencies De La Salut Germans Trias I Pujol | Badalona Barcelona | Spain | Third party |
| Pfizer SLU | Madrid | Spain | Associatedpartner |
| Biocorp Production | Issoire | France | Participant |
| Institut De Recherches Internationales Servier | Gif-Sur-Yvette | France | Participant |
| Lilly France | Neuilly-sur-Seine Cedex | France | Associatedpartner |
| Servier Affaires Medicales | Suresnes | France | Associatedpartner |
| Servier International | Suresnes | France | Associatedpartner |
| The European Coalition for People Living with Obesity Company Limited by Guarantee | Dublin | Ireland | Participant |
| Bar Ilan University | Ramat Gan | Israel | Participant |
| Israel Diabetes Association | Rishon Lezyion | Israel | Participant |
| A. Menarini - Industrie Farmaceutiche Riunite SRL | Firenze | Italy | Associatedpartner |
| Menarini Ricerche SpA | Pomezia | Italy | Participant |
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Participant |
| Imagine AI B.V. | Utrecht | Netherlands | Participant |
| Mama Producties BV | Eindhoven | Netherlands | Participant |
| Rijksuniversiteit Groningen | Groningen | Netherlands | Participant |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Stichting Vu | Amsterdam | Netherlands | Participant |
| Wavy Assistant BV | Groningen | Netherlands | Participant |
| Ogolnopolskie Stowarzyszenie Pacjentow ze Schorzeniami Serca i Naczyn Ecoserce | Milosc | Poland | Participant |
| Thaumatec SP ZOO | Wroclaw | Poland | Participant |
| Uniwersytet Medyczny W Lodzi | Lodz | Poland | Participant |
| Riksforbundet HjartLung | Stockholm | Sweden | Participant |
| Vastra Gotalandsregionen | Vanersborg | Sweden | Participant |
| Pfizer Limited | Sandwich | United Kingdom | Associatedpartner |
| Pfizer R&D UK Limited | Sandwich | United Kingdom | Associatedpartner |
| Eli Lilly and Company | Indianapolis | United States | Participant |
| Pfizer Inc | New York City | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI